Insulet (NASDAQ:PODD) Announces Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Insulet (NASDAQ:PODD) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15, Zacks reports. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Insulet Stock Performance

Insulet stock opened at $282.80 on Friday. The company has a market cap of $19.84 billion, a PE ratio of 48.84, a P/E/G ratio of 3.62 and a beta of 1.23. The company has a fifty day moving average price of $272.98 and a two-hundred day moving average price of $247.11. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet has a 12 month low of $160.19 and a 12 month high of $289.46.

Insiders Place Their Bets

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a research report on Friday. BTIG Research increased their price objective on shares of Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Citigroup increased their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday. Finally, Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $289.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.